Showing posts with label mutation. Show all posts
Showing posts with label mutation. Show all posts

Monday, 19 August 2013

Researchers link PRKG1 genetic mutation to thoracic aortic disease

Main Category: Heart Disease
Also Included In: Genetics
Article Date: 19 Aug 2013 - 1:00 PDT Current ratings for:
Researchers link PRKG1 genetic mutation to thoracic aortic disease
not yet ratednot yet rated

A multi-institutional team led by Dianna Milewicz, M.D., Ph.D., of The University of Texas Health Science Center at Houston (UTHealth) has found a recurrent genetic mutation that has been linked to deadly thoracic aortic dissections in family members as young as 17 years of age.

The gene known as PRKG1 makes a protein called cGMP-dependent kinase, type I. The PRKG1 mutation alters the function of the protein and causes the muscle cells in the wall of the aorta to respond incorrectly to pulsatile blood flow from the heart, and the change in this one protein ultimately causes thoracic aortic aneurysm and acute aortic dissection. The mutation was identified in four families, including three in the United States. The majority of the affected family members suffered acute aortic dissections at young ages (17 to 51 years).

"What is unique about this finding is that we identified four unrelated families from around the world and of different ethnicities who have the exact same genetic mutation, which is one altered base pair out of the 3 billion base pairs that make up our DNA," said Milewicz, senior author of the study. "The protein is normally regulated but this mutation causes the protein to be always active, almost like the brakes have gone out on a car and it cannot stop." The study was published in the online issue of the American Journal of Human Genetics. Milewicz is professor and director of the Division of Genetics at the UTHealth Medical School and holds the President George H.W. Bush Chair in Cardiovascular Research. She is also on the faculty of The University of Texas Graduate School of Biomedical Sciences and director of the John Ritter Research Program in Aortic and Vascular Disease.

For families in the study, knowing who carries the gene defect could help them make important medical decisions.

"The fact we will have a positive identification gives us a clearer picture of what to do next," said Stephen Harris of Montana, who lost one of his four daughters to the disease. "If my daughters are not carrying the gene defect, it gives them more freedom to have a baby. And they can make a decision about whether to have elective surgery sooner."

In thoracic aortic disease, the wall of the aorta, the main blood vessel leading out of the heart, weakens and forms an aneurysm that can ultimately lead to an aortic dissection and death. There are few symptoms until the aorta begins to dissect, or tear, requiring emergency surgery. Thoracic aortic aneurysms and dissections are familial in up to 20 percent of all cases. Researchers have now discovered nine different genes linked to familial thoracic aortic disease. Family members who have inherited the mutated gene will need to be monitored by a cardiologist, undergo regular imaging of the aorta and take medications to control high blood pressure and reduce the stress on the aorta. When the aorta enlarges to a certain size, elective surgery can be performed in order to avoid emergency repair to attempt to repair a catastrophic aortic dissection or rupture. . Using this management protocol, acute aortic dissections and the associated premature deaths can be prevented.

Stephen Harris' brother was the first to have symptoms of an aortic dissection when he was 51 years old and was found to have a descending thoracic aortic dissection. Cheryl Harris, Stephen's wife, said their daughter Jenny was eight months pregnant in 2006 when she began to have severe pain in her back just like her uncle but since aortic disease mostly affects older men, they didn't connect it to her. She died suddenly six days later from a dissected aorta and the baby also did not survive. In June of 2012, daughter Andra Arterbury, then 27, felt the classic symptom of extreme back pain, which radiated into her neck. She insisted on a scan at the hospital emergency room and went immediately to life-saving surgery when it showed that the aorta was dissected up into her carotid artery and down nearly to her groin.

Steve Harris traveled to Houston to consult with Milewicz and the clinical team at the Multidisciplinary Aortic and Vascular Disease Clinic. He was also found to have aortic root dilation and because of his family history of early thoracic aortic dissections at diameters smaller than 5 centimeters, he elected to have surgery. In October 2012, Anthony Estrera, M.D., associate professor of cardiovascular surgery at the UTHealth Medical School and the Memorial Hermann Heart and Vascular Institute, performed the graft replacement of his aortic root.

Wendy Amaya, 40, of Albuquerque and her family members have also suffered from the disease. Her mother, 43; brother, 35; and nephew, 23, all died from thoracic aortic dissections. Her 19-year-old son required surgery to repair a dissection in 2012 and another son has an aneurysm that is being monitored. Amaya had surgical repairs for her aorta in 2004 and 2012.

"The imaging is expensive, so it's important to find out if they have the genetic mutation. I have younger children and nieces and nephews," Amaya said. Now that the causative genetic mutation has been identified, genetic testing can identify family members who carry the familial mutation and need aortic surveillance.

Of the individuals who have the mutation, 63 percent had acute aortic dissections and 37 percent have aortic root enlargement. Of the 19 family members with dissections, five had a diagnosis of hypertension and five had evidence of damage associated with hypertension such as left ventricular hypertrophy or chronic small vessel cerebrovascular disease.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our heart disease section for the latest news on this subject.

Recurrent Gain-of-Function Mutation in PRKG1 Causes Thoracic Aortic Aneurysms and Acute Aortic Dissections

The American Journal of Human Genetics, Volume 93, Issue 2, 398-404, 01 August 2013 doi:10.1016/j.ajhg.2013.06.019

First author of the paper is Dong-chuan Guo, Ph.D., assistant professor of genetics at UTHealth. Co-authors from UTHealth are Ellen Regalado, M.S., genetic counselor and instructor; Limin Gong, assistant professor; and Guijuan Ghang, M.D., postdoctoral fellow.

Co-authors and investigators throughout world include Darren Casteel, Ph.D., of the University of California at San Diego; Guillaume Jondeau and Catherine Boileau from the Institut National de la Sante et de la Recherche Medicále of France; Jay Shendure, Mark J. Rieder, Michael J. Bamshad and Deborah Nickerson, Ph.D., from the University of Washington; Suzanne Leal, Ph.D., Regie Santos-Cortez, M.D., Ph.D., Joseph Coselli, M.D., and Choel Kim, Ph.D., from Baylor College of Medicine; Sarah Dyack and S. Gabrielle Horne, from Dalhousie University, Halifax, Nova Scotia, Canada; and the GenTAC Registry Consortium (HHSN268200648199C and HHSN268201000048C).

Funding for the research came from the National Heart, Lung and Blood Institute (NHLBI) (R01 HL62594 and P50HKL083794-01), part of the National Institutes of Health; the Vivian L. Smith Foundation; and the Tex-Gen Foundation. French and European sources provided funding for the Paris investigators. Support was also received from the NHLBI GO Exome Sequencing Project (HL-102926).

University of Texas Health Science Center at Houston

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Texas Health Science Center at Houst. "Researchers link PRKG1 genetic mutation to thoracic aortic disease." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
19 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Researchers link PRKG1 genetic mutation to thoracic aortic disease'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, 1 August 2013

Identification of genetic mutation linked to congenital heart disease

Main Category: Heart Disease
Also Included In: Genetics
Article Date: 31 Jul 2013 - 0:00 PDT Current ratings for:
Identification of genetic mutation linked to congenital heart disease
not yet ratednot yet rated

A mutation in a gene crucial to normal heart development could play a role in some types of congenital heart disease - the most common birth defect in the U.S. The finding, from a team in The Research Institute at Nationwide Children's Hospital, could help narrow the search for genes that contribute to this defect, which affects as many as 40,000 newborns a year. The findings were published in a recent issue of in Human Mutation.

Several hundred genes have been implicated in the formation of the heart, and a mutation in any of them could potentially contribute to a cardiac defect. Identifying which of these genes is involved in human congenital heart disease has been a challenge for scientists in the field, says Vidu Garg, MD, senior author of the new study, principal investigator in the Center for Cardiovascular and Pulmonary Research and director of Translational Research in The Heart Center at Nationwide Children's.

"We have to ask ourselves, what subset of the more than 20,000 genes that make up the human genome are contributing to congenital heart disease?" he says. "Right now, we don't know enough about a lot of those genes, so this study provides another piece of the puzzle."

That piece is FOXP1, a member of a large gene family that helps regulate tissues throughout the body, including in the heart, lungs and brain. A few studies on FOXP1 had described its function and role in cardiac development in animal models, but it wasn't until a former colleague called with an interesting case that Dr. Garg decided the gene was worth a closer look.

While analyzing a DNA sample from an 8-month-old infant who died from complications of complex congenital heart disease, Linda Baker, MD, at the University of Texas Southwestern Medical Center, had found a rare genetic abnormality - a small chromosomal deletion - in the patient's FOXP1 gene.

A search of DNA samples from patients with congenital heart disease in a repository at Nationwide Children's - one of the largest in the nation - revealed two additional patients with a similar complex heart defect who had a rare mutation in the same gene. On further analysis, Dr. Garg's team found that this mutation affected the gene's ability to express a transcription factor called Nkx2.5, which has been implicated in congenital heart disease.

"If you have three unrelated people with an abnormality in the same gene, and they also have an extremely rare type of congenital heart disease, there's a high likelihood that the gene is contributing to the condition," says Dr. Garg, who also is an associate professor of pediatrics at The Ohio State University College of Medicine. "Understanding how either deletion or loss of FOXP1 affects normal heart development could help contribute to our understanding of congenital heart disease."

The next step in the research is to see if they can find the FOXP1 mutation in patients with different types of congenital heart disease. From there, they will begin to look at how the gene interacts with others involved in the formation of a normal heart. Given that congenital heart disease is probably the result of mutations in many genes, Dr. Garg says, it's quite possible that by studying this gene and its potential partners, we can uncover other potential candidate genes for heart malformations.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our heart disease section for the latest news on this subject.

Chang, S.-W., Mislankar, M., Misra, C., Huang, N., DaJusta, D. G., Harrison, S. M., McBride, K. L., Baker, L. A. and Garg, V. (2013), Genetic Abnormalities in FOXP1 Are Associated with Congenital Heart Defects. Hum. Mutat.. doi: 10.1002/humu.22366

Nationwide Children's Hospital

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Hospital, Nationwide Children\'s. "Identification of genetic mutation linked to congenital heart disease." Medical News Today. MediLexicon, Intl., 31 Jul. 2013. Web.
31 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Identification of genetic mutation linked to congenital heart disease'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, 30 July 2013

EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued

Main Category: Lung Cancer
Article Date: 29 Jul 2013 - 1:00 PDT Current ratings for:
EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued
not yet ratednot yet rated

Significant advances have taken place in the management of patients with advanced and metastatic non-small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation status is predictive of improved survival and quality of life with selected systemic therapies.

Researchers in Canada examined the barriers to the initial implementation of the national EGFR testing policy. In the September issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO), researchers conclude that the uptake of EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued.

The Canadian health care system is publicly funded through each province or territory. EGFR mutation testing was not available in Canada outside of research laboratories before March 2010. Five laboratories across the country undertook validation and quality-control processes to establish a network for EGFR mutation testing using reverse transcriptase-polymerase chain reaction. Laboratories were reimbursed for testing by AstraZeneca Canada for an initial 12 months. Patients were eligible for EGFR mutation testing if they had advanced/metastatic NSCLC and non-squamous histology.

At the end of 12 months, when the EGFR mutation testing and associated compassionate gefitinib program supported by AstraZeneca were completed, there was a substantial drop in the number of EGFR test requests. Over the next 6 months, the number of tests performed monthly ranged from 50 to 120 in comparison to 200 to 250 tests per month in the first 12 months.

Researchers conclude, "there is a need for a national strategy to ensure resources are in place to implement molecular testing for new molecularly targeted agents."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our lung cancer section for the latest news on this subject.

The lead author is IASLC member Dr. Peter Ellis. Dr. Natasha Leighl is a co-author and IASLC member.

International Association for the Study of Lung Cancer

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued." Medical News Today. MediLexicon, Intl., 29 Jul. 2013. Web.
29 Jul. 2013. APA
International Association for the Study of Lung Ca. (2013, July 29). "EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/264015.php.

Please note: If no author information is provided, the source is cited instead.


'EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued

Main Category: Lung Cancer
Article Date: 29 Jul 2013 - 1:00 PDT Current ratings for:
EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued
not yet ratednot yet rated

Significant advances have taken place in the management of patients with advanced and metastatic non-small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation status is predictive of improved survival and quality of life with selected systemic therapies.

Researchers in Canada examined the barriers to the initial implementation of the national EGFR testing policy. In the September issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO), researchers conclude that the uptake of EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued.

The Canadian health care system is publicly funded through each province or territory. EGFR mutation testing was not available in Canada outside of research laboratories before March 2010. Five laboratories across the country undertook validation and quality-control processes to establish a network for EGFR mutation testing using reverse transcriptase-polymerase chain reaction. Laboratories were reimbursed for testing by AstraZeneca Canada for an initial 12 months. Patients were eligible for EGFR mutation testing if they had advanced/metastatic NSCLC and non-squamous histology.

At the end of 12 months, when the EGFR mutation testing and associated compassionate gefitinib program supported by AstraZeneca were completed, there was a substantial drop in the number of EGFR test requests. Over the next 6 months, the number of tests performed monthly ranged from 50 to 120 in comparison to 200 to 250 tests per month in the first 12 months.

Researchers conclude, "there is a need for a national strategy to ensure resources are in place to implement molecular testing for new molecularly targeted agents."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our lung cancer section for the latest news on this subject.

The lead author is IASLC member Dr. Peter Ellis. Dr. Natasha Leighl is a co-author and IASLC member.

International Association for the Study of Lung Cancer

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued." Medical News Today. MediLexicon, Intl., 29 Jul. 2013. Web.
29 Jul. 2013. APA
International Association for the Study of Lung Ca. (2013, July 29). "EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/264015.php.

Please note: If no author information is provided, the source is cited instead.


'EGFR mutation testing dropped substantially once funding from the pharmaceutical industry was discontinued'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here